- Home
- RMCO vs EDSA Comparison
RMCO vs EDSA Comparison
Compare RMCO & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- EDSA
- Stock Information
- Founded
- RMCO 2021
- EDSA 2015
- Country
- RMCO United States
- EDSA Canada
- Employees
- RMCO N/A
- EDSA N/A
- Industry
- RMCO Multi-Sector Companies
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- EDSA Health Care
- Exchange
- RMCO Nasdaq
- EDSA Nasdaq
- Market Cap
- RMCO 14.8M
- EDSA 6.1M
- IPO Year
- RMCO N/A
- EDSA N/A
- Fundamental
- Price
- RMCO $1.18
- EDSA $1.73
- Analyst Decision
- RMCO
- EDSA Strong Buy
- Analyst Count
- RMCO 0
- EDSA 1
- Target Price
- RMCO N/A
- EDSA $21.00
- AVG Volume (30 Days)
- RMCO 39.4K
- EDSA 30.6K
- Earning Date
- RMCO 01-24-2025
- EDSA 02-07-2025
- Dividend Yield
- RMCO N/A
- EDSA N/A
- EPS Growth
- RMCO N/A
- EDSA N/A
- EPS
- RMCO N/A
- EDSA N/A
- Revenue
- RMCO $568,896.00
- EDSA N/A
- Revenue This Year
- RMCO N/A
- EDSA N/A
- Revenue Next Year
- RMCO N/A
- EDSA N/A
- P/E Ratio
- RMCO N/A
- EDSA N/A
- Revenue Growth
- RMCO 21.05
- EDSA N/A
- 52 Week Low
- RMCO $0.70
- EDSA $1.55
- 52 Week High
- RMCO $4.75
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- RMCO 61.39
- EDSA 31.51
- Support Level
- RMCO $0.96
- EDSA $1.73
- Resistance Level
- RMCO $1.28
- EDSA $1.99
- Average True Range (ATR)
- RMCO 0.11
- EDSA 0.19
- MACD
- RMCO 0.02
- EDSA 0.02
- Stochastic Oscillator
- RMCO 73.68
- EDSA 18.00
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.